Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.54 |
| ▸ | MAP4K3 | Q8IVH8 | 10/20 | 0.50 |
| ▸ | AXL | P30530 | 1/20 | 0.46 |
| ▸ | MERTK | Q12866 | 1/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.45 |
| ▸ | FGFR2 | P21802 | 5/20 | 0.45 |
| ▸ | FGFR3 | P22607 | 5/20 | 0.45 |
| ▸ | ATR | Q13535 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4038434 | 0.88 | EGFR (0.57) | EGFRMAP4K3FGFR1FGFR2FGFR3 | |
| SCHEMBL4035619 | 0.88 | EGFR (0.55) | EGFRMAP4K3FGFR1FGFR2FGFR3 | |
| SCHEMBL4044869 | 0.86 | MAP4K3 (0.56) | EGFRMAP4K3AXLMERTKFGFR1 | |
| SCHEMBL4052605 | 0.86 | EGFR (0.55) | EGFRMAP4K3NTRK1FGFR1FGFR2 | |
| SCHEMBL4052067 | 0.85 | EGFR (0.55) | EGFRMAP4K3AXLMERTKFGFR1 | |
| SCHEMBL4045036 | 0.84 | EGFR (0.57) | EGFRMAP4K3NTRK1FGFR1FGFR2 | |
| SCHEMBL4045866 | 0.83 | EGFR (0.50) | EGFRMAP4K3FGFR1FGFR2FGFR3 | |
| SCHEMBL4048973 | 0.83 | EGFR (0.50) | EGFRMAP4K3AXLMERTKFGFR1 | |
| SCHEMBL4036451 | 0.82 | EGFR (0.62) | EGFRMAP4K3FGFR1FGFR2FGFR3 | |
| SCHEMBL3952099 | 0.82 | EGFR (0.59) | EGFRMAP4K3FGFR1FGFR2FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009024825-A1 | 2-PYRAZINYLBENZIMIDAZOLE DERIVATIVES AS RECEPTOR TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | WO | disclosed |
| US-7479564-B2 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | RAQUALIA PHARMA INC. (JP) | 2009-01-20 | — | — | US | disclosed |
| US-20070155732-A1 | Aryl or Heteroaryl Fused Imidazole Compounds as Anti-Inflammatory and Analgesic Agents | PFIZER INC. | 2007-07-05 | — | — | US | disclosed |
| US-7148234-B2 | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases | PFIZER INC. (US) | 2006-12-12 | — | — | US | disclosed |
| US-7141580-B2 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | PFIZER INC. (US) | 2006-11-28 | — | — | US | disclosed |
| EP-1666480-A1 | Aryl or Heteroaryl Fused Imidazole Compounds as intermediates for Anti-Inflammatory And Analgesic Agents. | PFIZER PHARMACEUTICALS INC. (JP) | 2006-06-07 | — | — | EP | disclosed |
| EP-1326864-B1 | ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | PFIZER PHARMA (JP) | 2006-03-15 | — | — | EP | disclosed |
| US-20040181059-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | ASKAT INC. (JP) | 2004-09-16 | — | — | US | disclosed |
| US-6710054-B2 | CONTAINING SULFONYLAMINOCARBONYL GROUPS; PROSTAGLANDIN INHIBITORS | PFIZER INC | 2004-03-23 | — | — | US | disclosed |
| US-20030236260-A1 | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases | SHIMOJO MASATO | 2003-12-25 | — | — | US | disclosed |
| US-20020107273-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | ASKAT INC. (JP) | 2002-08-08 | — | — | US | disclosed |
| US-20020077329-A1 | EP4 receptor inhibitors to treat rheumatoid arthritis | PFIZER PHARMACEUTICALS INC. (JP) | 2002-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107273-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | PTGS1, PTGS2, OPRM1 | EGFR 4138/4885MAP4K3 2598/4885AXL 4837/4885 |
| US-20030236260-A1 | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases | PTGER4, PTGER1, IL6 | EGFR 1966/4885MAP4K3 906/4885AXL 3412/4885 |
| US-20040181059-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | PTGS1, PTGS2, OPRM1 | EGFR 4161/4885MAP4K3 2604/4885AXL 4841/4885 |
| US-20070155732-A1 | Aryl or Heteroaryl Fused Imidazole Compounds as Anti-Inflammatory and Analgesic Agents | PTGS1, PTGS2, PTGES | EGFR 3743/4885MAP4K3 2096/4885AXL 4671/4885 |
| US-20020077329-A1 | EP4 receptor inhibitors to treat rheumatoid arthritis | PTGER4, PTGER1, PTGER2 | EGFR 883/4885MAP4K3 656/4885AXL 3999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.